An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxopiperidin-4-ylcarbamoyl} -cyclohexyl-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 2, 2006, Pages 555-562

  Kim, M K ^a   Kim, H D ^a   Park, J H ^a   Lim, J I ^a   Yang, J S ^a   Kwak, W Y ^a   Sung, S Y ^a   Kim, H J ^a   Kim, S H ^a   Lee, C H ^b   Shim, J Y ^b   Bae, M H ^b   Shin, Y A ^b   Huh, Y ^b   Han, T D ^b   Chong, W ^b   Choi, H ^b   Ahn, B N ^b   Yang, S O ^c   Son, M H ^a,d  

^a Dong A Pharmaceutical Company   (South Korea)

^b Yuhan Corporation   (South Korea)

^c Eulji University   (South Korea)

^d NONE   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 FUROIC ACID; ALKALINE PHOSPHATASE; CATHEPSIN K; CATHEPSIN K INHIBITOR; DEOXYPYRIDINOLINE; FURAN 2 CARBOXYLIC ACID[1 [1 [4 FLUORO 2 (2 OXO PYRROLIDIN 1 YL)PHENYL] 3 OXO PIPERIDIN 4 YLCARBAMOYL]CYCLOHEXYL]AMIDE; OST 4077; OSTEOCALCIN; PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE DENSITOMETRY; BONE MINERALIZATION; CELL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; MALE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; THYROPARATHYROIDECTOMY; URINARY EXCRETION;

ALKALINE PHOSPHATASE; AMIDES; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CATHEPSINS; CLONING, MOLECULAR; ENZYME INHIBITORS; ESTROGENS; FEMALE; FURANS; HUMANS; OSTEOCLASTS; OVARIECTOMY; PARATHYROID HORMONE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33745952369     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.102798     Document Type: Article

References (26)

1. Aibe K, Yazawa H, Abe K, Teramura K, Kumegawa M, Kawashima H, and Honda K (1996) Substrate specificity of recombinant osteoclast-specific cathepsin K from rabbits. Biol Pharm Bull 19:1026-1031.
2. Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, et al. (1996) Proteolytic activity of human osteoclast cathepsin K. J Biol Chem 271:12517-12524.
3. Bromme D, Okamoto K, Wang BB, and Biroc S (1996) Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. J Biol Chem 271:2126-2132.
4. Caselli G, Mantovanini M, Gandolfi CA, Allegretti M, Fiorentino S, Pellegrini L, Melillo G, Bertini R, Sabbatini W, Anacardio R, et al. (1997) Tartronates: a new generation of drugs affecting bone metabolism. J Bone Miner Res 12:972-981.
5. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, et al. (1996) Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 271:12511-12516.
6. Einhorn TA (1996) The bone organ system: form and function, in Osteoporosis (Marcus R, Feldman D, and Kelsey J eds) pp 3-22, Academic Press, New York.
7. Fujikawa Y, Sabokbar A, Neale SD, Itonaga I, Torisu T, and Athanasou NA (2001) The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-α, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone (NY) 28:261-267.
8. Gelb BD, Shi GP, Chapman HA, and Desnick RJ (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science (Wash DC) 273:1236-1238.
9. Hou WS, Bromme D, Zhao Y, Mehler E, Dushey C, Weinstein H, Miranda CS, Fraga C, Greig F, Carey J, et al. (1999) Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J Clin Investig 103:731-738.
10. Kamiya T, Kobayashi Y, Kanaoka K, Nakashima T, Kato Y, Mizuno A, and Sakai H (1998) Fluorescence microscopic demonstration of cathepsin K activity as the major lysosomal cysteine proteinase in osteoclasts. J Biochem (Tokyo) 123:752-759.
11. Kaneko H, Arakawa T, Mano H, Kaneda T, Ogasawara A, Nakagawa M, Toyama Y, Yabe Y, Kumegawa M, and Hakeda Y (2000) Direct stimulation of osteoclastic bone resorption by bone morphogentic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone (NY) 27:479-486.
12. Lark MW, Stroup GB, James IE, Dodds RA, Hwang SM, Blake SM, Lechowska BA, Hoffman SJ, Smith BR, Kapadia R, et al. (2002) A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone (NY) 30:746-753.
13. Linnevers CJ, McGrath ME, Armstrong R, Mistry FR, Barnes MG, Klaus JL, Palmer JT, Katz BA, and Bromme D (1997) Expression of human cathepsin K in Pichia pastoris and preliminary crystallographic studies of an inhibitor complex. Protein Sci 6:919-921.
14. Littlewood-Evans AJ, Bilbe G, Bowler WB, Farley D, Wlodarski B, Kokubo T, Inaoka T, Sloane J, Evans DB, and Gallagher JA (1997) The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57:5386-5390.
15. Massey HM, Scopes J, Horton HA, and Flanagan AM (2001) Transforming Growth Factor-β1(TGF-β) stimulates the osteoclast-forming potential of peripheral blood hematopoietic precursors in a lymphocyte-rich microenvironment. Bone (NY) 28:577-582.
16. McQueney MS, Feild J, Hanning CR, Brun K, Ramachandran K, Connor J, Drake F, Jones CS, and Amegadzie BY (1998) Cynomolgus monkey (Macaca fascicularis) cathepsin K: cloning, expression, purification, and activation. Protein Exp Purif 14:387-394.
17. Mitsudo K, Jayakumar A, Henderson Y, Frederick MJ, Kang Y, Wang M, El-Naggar AK, and Clayman GL (2003) Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis. Biochemistry 42:3874-3881.
18. Pennypacker BL, Shea M, Saftig P, Rodan SB, Rodan GA, and Kimmel DB (1999) Bone density and strength in cathepsin K null mice. J Bone Miner Res 14:S549.
19. Pennypacker BL, Cusick T, Masarachia P, and Kimmel DB (2004) Effect of alendronate in a lapine model of estrogen deficiency. J Bone Miner Res 19:S444.
20. Rodan GA, Seedor JG, and Balena R (1993) Preclinical pharmacology of alendronate. Osteoporos Int 3:S7-12.
21. Saftig P, Hunziker E, Wehmeyer O, Johnes S, Boyde A, Rommerskirch W, Moritz JD, Schu P, and Figura K (1998) Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:13453-13458.
22. Spinella-Jaegle S, Roman-Roman S, Fauchen C, Dunn FW, Kawai S, Gallea S, Stoit V, Blanchet AM, Courtois B, Baron R, et al. (2001) Opposite effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on osteoblast differentiation. Bone (NY) 29:323-330.
23. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, et al. (2001) Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 16:1739-1746.
24. Tepel C, Bromme D, Herzog V, and Brix K (2000) Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulin. J Cell Sci 113:4487-4498.
25. Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, James IE, Thompson S, Bossard MJ, Carr T, Connor JR, et al. (1997) Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 12:1396-1406.
26. Yasuma T, Oi S, Choh N, Nomura T, Furuyama N, Nishimura A, Fujisawa Y, and Sohda T (1998) Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption. J Med Chem 41:4301-4308.